Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

20.06.2022 | Review

Association between sex and Huntington’s disease: an updated review on symptomatology and prognosis of neurodegenerative disorders

verfasst von: Nimra Hasnain, MBBS Taha Bin Arif, Roha Shafaut, Faiza Zakaria, Syeda Zainab Fatima, Ibtehaj Ul Haque

Erschienen in: Wiener Medizinische Wochenschrift

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Huntington’s disease is a rare autosomal dominant disorder presenting with chorea, rigidity, hypo-/akinesia, cognitive decline, and psychiatric disturbances. Numerous risk factors have been defined in the onset of this disease. However, the number of CAG repeats in the genes are the most crucial factor rendering patients susceptible to the disease. Studies have shown significant differences in onset and disease presentation among the sexes, which prompts analysis of the impact of different sexes on disease etiology and progression. This article therefore discusses the evidence-based role of sex in aspects of symptomatology, pathogenesis, biomarkers, progression, and prognosis of Huntington’s disease, with a secondary review of sex-linked differences in Alzheimer’s and Parkinson’s disease.
Literatur
1.
Zurück zum Zitat Ajitkumar A, De Jesus O. Huntington disease. Treasure Island (FL): StatPearls; 2021. Ajitkumar A, De Jesus O. Huntington disease. Treasure Island (FL): StatPearls; 2021.
4.
Zurück zum Zitat No authors listed. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s disease collaborative research group. Cell. 1993;72(6):971–83. CrossRef No authors listed. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s disease collaborative research group. Cell. 1993;72(6):971–83. CrossRef
5.
Zurück zum Zitat Quarrell O, O’Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington’s disease: a review of the literature and meta-analysis. PLoS Curr. 2012;4:e4f8606b742ef3. PubMedPubMedCentralCrossRef Quarrell O, O’Donovan KL, Bandmann O, Strong M. The prevalence of juvenile Huntington’s disease: a review of the literature and meta-analysis. PLoS Curr. 2012;4:e4f8606b742ef3. PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Zühlke C, Riess O, Schröder K, Siedlaczck I, Epplen JT, Engel W, et al. Expansion of the (CAG)n repeat causing Huntington’s disease in 352 patients of German origin. Hum Mol Genet. 1993;2(9):1467–9. PubMedCrossRef Zühlke C, Riess O, Schröder K, Siedlaczck I, Epplen JT, Engel W, et al. Expansion of the (CAG)n repeat causing Huntington’s disease in 352 patients of German origin. Hum Mol Genet. 1993;2(9):1467–9. PubMedCrossRef
7.
Zurück zum Zitat Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66(1):52–6. PubMedPubMedCentralCrossRef Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66(1):52–6. PubMedPubMedCentralCrossRef
8.
Zurück zum Zitat Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2(10):1535–40. PubMedCrossRef Telenius H, Kremer HP, Theilmann J, Andrew SE, Almqvist E, Anvret M, et al. Molecular analysis of juvenile Huntington disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet. 1993;2(10):1535–40. PubMedCrossRef
9.
Zurück zum Zitat Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. J Med Genet. 1994;31(5):377–82. PubMedPubMedCentralCrossRef Trottier Y, Biancalana V, Mandel JL. Instability of CAG repeats in Huntington’s disease: relation to parental transmission and age of onset. J Med Genet. 1994;31(5):377–82. PubMedPubMedCentralCrossRef
10.
Zurück zum Zitat Nørremølle A, Sørensen SA, Fenger K, Hasholt L. Correlation between magnitude of CAG repeat length alterations and length of the paternal repeat in paternally inherited Huntington’s disease. Clin Genet. 1995;47(3):113–7. PubMedCrossRef Nørremølle A, Sørensen SA, Fenger K, Hasholt L. Correlation between magnitude of CAG repeat length alterations and length of the paternal repeat in paternally inherited Huntington’s disease. Clin Genet. 1995;47(3):113–7. PubMedCrossRef
11.
Zurück zum Zitat Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999;36(2):108–11. PubMedPubMedCentral Kehoe P, Krawczak M, Harper PS, Owen MJ, Jones AL. Age of onset in Huntington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet. 1999;36(2):108–11. PubMedPubMedCentral
12.
Zurück zum Zitat Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 2007;44(11):695–701. PubMedPubMedCentralCrossRef Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, et al. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet. 2007;44(11):695–701. PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–81. PubMedPubMedCentralCrossRef Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90(5):1977–81. PubMedPubMedCentralCrossRef
14.
Zurück zum Zitat Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61. PubMedCrossRef Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet. 1996;14(1):55–61. PubMedCrossRef
15.
Zurück zum Zitat Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995;1(2):135–7. PubMedCrossRef Nicoll JA, Roberts GW, Graham DI. Apolipoprotein E epsilon 4 allele is associated with deposition of amyloid beta-protein following head injury. Nat Med. 1995;1(2):135–7. PubMedCrossRef
17.
Zurück zum Zitat Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, et al. The influence of gender on phenotype and disease progression in patients with Huntington’s disease. Parkinsonism Relat Disord. 2013;19(2):192–7. PubMedCrossRef Zielonka D, Marinus J, Roos RA, De Michele G, Di Donato S, Putter H, et al. The influence of gender on phenotype and disease progression in patients with Huntington’s disease. Parkinsonism Relat Disord. 2013;19(2):192–7. PubMedCrossRef
18.
Zurück zum Zitat Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, et al. The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington’s disease. Parkinsonism Relat Disord. 2018;49:42–7. PubMedCrossRef Zielonka D, Ren M, De Michele G, Roos RAC, Squitieri F, Bentivoglio AR, et al. The contribution of gender differences in motor, behavioral and cognitive features to functional capacity, independence and quality of life in patients with Huntington’s disease. Parkinsonism Relat Disord. 2018;49:42–7. PubMedCrossRef
20.
Zurück zum Zitat Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia. 2007;45(8):1767–76. PubMedPubMedCentralCrossRef Solomon AC, Stout JC, Johnson SA, Langbehn DR, Aylward EH, Brandt J, et al. Verbal episodic memory declines prior to diagnosis in Huntington’s disease. Neuropsychologia. 2007;45(8):1767–76. PubMedPubMedCentralCrossRef
21.
Zurück zum Zitat Filoteo JV, Delis DC, Roman MJ, Demadura T, Ford E, Butters N, et al. Visual attention and perception in patients with Huntington’s disease: comparisons with other subcortical and cortical dementias. J Clin Exp Neuropsychol. 1995;17(5):654–67. PubMedCrossRef Filoteo JV, Delis DC, Roman MJ, Demadura T, Ford E, Butters N, et al. Visual attention and perception in patients with Huntington’s disease: comparisons with other subcortical and cortical dementias. J Clin Exp Neuropsychol. 1995;17(5):654–67. PubMedCrossRef
22.
Zurück zum Zitat Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington’s disease. Huntington study group. Neurology. 2000;54(2):452–8. PubMedCrossRef Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington’s disease. Huntington study group. Neurology. 2000;54(2):452–8. PubMedCrossRef
23.
Zurück zum Zitat Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, et al. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology. 2010;75(1):57–63. PubMedCrossRef Saleh N, Moutereau S, Azulay JP, Verny C, Simonin C, Tranchant C, et al. High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology. 2010;75(1):57–63. PubMedCrossRef
24.
Zurück zum Zitat López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, et al. What is the impact of education on Huntington’s disease? Mov Disord. 2011;26(8):1489–95. PubMedCrossRef López-Sendón JL, Royuela A, Trigo P, Orth M, Lange H, Reilmann R, et al. What is the impact of education on Huntington’s disease? Mov Disord. 2011;26(8):1489–95. PubMedCrossRef
26.
Zurück zum Zitat Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC. Clinical expression of essential tremor: effects of gender and age. Mov Disord. 1997;12(6):969–72. PubMedCrossRef Hubble JP, Busenbark KL, Pahwa R, Lyons K, Koller WC. Clinical expression of essential tremor: effects of gender and age. Mov Disord. 1997;12(6):969–72. PubMedCrossRef
27.
Zurück zum Zitat Hardesty DE, Maraganore DM, Matsumoto JY, Louis ED. Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester epidemiology project. Mov Disord. 2004;19(5):529–33. PubMedCrossRef Hardesty DE, Maraganore DM, Matsumoto JY, Louis ED. Increased risk of head tremor in women with essential tremor: longitudinal data from the Rochester epidemiology project. Mov Disord. 2004;19(5):529–33. PubMedCrossRef
28.
Zurück zum Zitat Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep. 2017;17(1):6. PubMedCrossRef Cossu G, Colosimo C. Hyperkinetic movement disorder emergencies. Curr Neurol Neurosci Rep. 2017;17(1):6. PubMedCrossRef
30.
Zurück zum Zitat van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–8. PubMedCrossRef van Duijn E, Craufurd D, Hubers AA, Giltay EJ, Bonelli R, Rickards H, et al. Neuropsychiatric symptoms in a European Huntington’s disease cohort (REGISTRY). J Neurol Neurosurg Psychiatry. 2014;85(12):1411–8. PubMedCrossRef
31.
Zurück zum Zitat Dale M, Maltby J, Shimozaki S, Cramp R, Rickards H. Disease stage, but not sex, predicts depression and psychological distress in Huntington’s disease: a European population study. J Psychosom Res. 2016;80:17–22. PubMedCrossRef Dale M, Maltby J, Shimozaki S, Cramp R, Rickards H. Disease stage, but not sex, predicts depression and psychological distress in Huntington’s disease: a European population study. J Psychosom Res. 2016;80:17–22. PubMedCrossRef
32.
Zurück zum Zitat Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. PubMedCrossRef Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011;21(9):655–79. PubMedCrossRef
33.
Zurück zum Zitat Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2–3):85–96. PubMedCrossRef Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the national comorbidity survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29(2–3):85–96. PubMedCrossRef
34.
Zurück zum Zitat Rowe KC, Paulsen JS, Langbehn DR, Wang C, Mills J, Beglinger LJ, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196(2–3):309–14. PubMedPubMedCentralCrossRef Rowe KC, Paulsen JS, Langbehn DR, Wang C, Mills J, Beglinger LJ, et al. Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res. 2012;196(2–3):309–14. PubMedPubMedCentralCrossRef
35.
36.
Zurück zum Zitat Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008;71(19):1506–13. PubMedCrossRef Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA. Weight loss in Huntington disease increases with higher CAG repeat number. Neurology. 2008;71(19):1506–13. PubMedCrossRef
37.
Zurück zum Zitat Costa de Miranda R, Di Lorenzo N, Andreoli A, Romano L, De Santis GL, Gualtieri P, et al. Body composition and bone mineral density in Huntington’s disease. Nutrition. 2019;59:145–9. PubMedCrossRef Costa de Miranda R, Di Lorenzo N, Andreoli A, Romano L, De Santis GL, Gualtieri P, et al. Body composition and bone mineral density in Huntington’s disease. Nutrition. 2019;59:145–9. PubMedCrossRef
38.
Zurück zum Zitat Beyer C, Pilgrim C, Reisert I. Dopamine content and metabolism in mesencephalic and diencephalic cell cultures: sex differences and effects of sex steroids. J Neurosci. 1991;11(5):1325–33. PubMedPubMedCentralCrossRef Beyer C, Pilgrim C, Reisert I. Dopamine content and metabolism in mesencephalic and diencephalic cell cultures: sex differences and effects of sex steroids. J Neurosci. 1991;11(5):1325–33. PubMedPubMedCentralCrossRef
39.
Zurück zum Zitat Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvalahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52(7):759–63. PubMedCrossRef Laakso A, Vilkman H, Bergman J, Haaparanta M, Solin O, Syvalahti E, et al. Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. Biol Psychiatry. 2002;52(7):759–63. PubMedCrossRef
40.
Zurück zum Zitat Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI. Gender differences in nigrostriatal dopaminergic innervation are present at young-to-middle but not at older age in normal adults. J Clin Neurosci. 2012;19(1):183–4. PubMedCrossRef Wong KK, Muller ML, Kuwabara H, Studenski SA, Bohnen NI. Gender differences in nigrostriatal dopaminergic innervation are present at young-to-middle but not at older age in normal adults. J Clin Neurosci. 2012;19(1):183–4. PubMedCrossRef
41.
Zurück zum Zitat Jankovic J, Hallett M, Okun MS, Comella CL, Fahn S. Principles and practice of movement disorders E‑book. Elsevier; 2021. Jankovic J, Hallett M, Okun MS, Comella CL, Fahn S. Principles and practice of movement disorders E‑book. Elsevier; 2021.
42.
Zurück zum Zitat Kara M, Smith ND. Sex differences in Parkinson’s disease and other movement disorders. Exp Neurol. 2014;259:44–56. CrossRef Kara M, Smith ND. Sex differences in Parkinson’s disease and other movement disorders. Exp Neurol. 2014;259:44–56. CrossRef
43.
Zurück zum Zitat Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54(12):2292–8. PubMedCrossRef Tsang KL, Ho SL, Lo SK. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology. 2000;54(12):2292–8. PubMedCrossRef
44.
Zurück zum Zitat Weaver CE Jr., Park-Chung M, Gibbs TT, Farb DH. 17beta-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 1997;761(2):338–41. PubMedCrossRef Weaver CE Jr., Park-Chung M, Gibbs TT, Farb DH. 17beta-estradiol protects against NMDA-induced excitotoxicity by direct inhibition of NMDA receptors. Brain Res. 1997;761(2):338–41. PubMedCrossRef
45.
Zurück zum Zitat Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro Endocrinol Lett. 2001;22(3):163–8. PubMed Hogervorst E, Williams J, Budge M, Barnetson L, Combrinck M, Smith AD. Serum total testosterone is lower in men with Alzheimer’s disease. Neuro Endocrinol Lett. 2001;22(3):163–8. PubMed
46.
Zurück zum Zitat Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59(5):807–11. PubMedCrossRef Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59(5):807–11. PubMedCrossRef
47.
Zurück zum Zitat Militello A, Vitello G, Lunetta C, Toscano A, Maiorana G, Piccoli T, et al. The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J Neurol Sci. 2002;195(1):67–70. PubMedCrossRef Militello A, Vitello G, Lunetta C, Toscano A, Maiorana G, Piccoli T, et al. The serum level of free testosterone is reduced in amyotrophic lateral sclerosis. J Neurol Sci. 2002;195(1):67–70. PubMedCrossRef
48.
Zurück zum Zitat Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington’s disease. Neuro Endocrinol Lett. 2007;28(2):199–203. PubMed Markianos M, Panas M, Kalfakis N, Vassilopoulos D. Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington’s disease. Neuro Endocrinol Lett. 2007;28(2):199–203. PubMed
49.
Zurück zum Zitat Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, et al. Neuroendocrine disturbances in Huntington’s disease. PLoS One. 2009;4(3):e4962. PubMedPubMedCentralCrossRef Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C, et al. Neuroendocrine disturbances in Huntington’s disease. PLoS One. 2009;4(3):e4962. PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT. Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. JAMA Neurol. 2019;76(4):470–9. PubMedPubMedCentralCrossRef De Pablo-Fernández E, Lees AJ, Holton JL, Warner TT. Prognosis and neuropathologic correlation of clinical subtypes of parkinson disease. JAMA Neurol. 2019;76(4):470–9. PubMedPubMedCentralCrossRef
51.
Zurück zum Zitat Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24. PubMedCrossRef Haaxma CA, Bloem BR, Borm GF, Oyen WJ, Leenders KL, Eshuis S, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819–24. PubMedCrossRef
52.
Zurück zum Zitat Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16(5):830–7. PubMedCrossRef Benedetti MD, Maraganore DM, Bower JH, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Hysterectomy, menopause, and estrogen use preceding Parkinson’s disease: an exploratory case-control study. Mov Disord. 2001;16(5):830–7. PubMedCrossRef
53.
Zurück zum Zitat Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908–16. PubMedPubMedCentralCrossRef Latourelle JC, Beste MT, Hadzi TC, Miller RE, Oppenheim JN, Valko MP, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson’s disease: a longitudinal cohort study and validation. Lancet Neurol. 2017;16(11):908–16. PubMedPubMedCentralCrossRef
54.
Zurück zum Zitat Melcangi RC, Giatti S, Garcia-Segura LM. Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: sex-specific features. Neurosci Biobehav Rev. 2016;67:25–40. PubMedCrossRef Melcangi RC, Giatti S, Garcia-Segura LM. Levels and actions of neuroactive steroids in the nervous system under physiological and pathological conditions: sex-specific features. Neurosci Biobehav Rev. 2016;67:25–40. PubMedCrossRef
55.
Zurück zum Zitat Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–9. PubMedCrossRef Lavalaye J, Booij J, Reneman L, Habraken JB, van Royen EA. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000;27(7):867–9. PubMedCrossRef
56.
Zurück zum Zitat Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol. 2020;16(2):84–96. PubMedCrossRef Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol. 2020;16(2):84–96. PubMedCrossRef
57.
Zurück zum Zitat Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet. 2007;122(2):175–82. PubMedCrossRef Arning L, Saft C, Wieczorek S, Andrich J, Kraus PH, Epplen JT. NR2A and NR2B receptor gene variations modify age at onset in Huntington disease in a sex-specific manner. Hum Genet. 2007;122(2):175–82. PubMedCrossRef
58.
Zurück zum Zitat Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics. 2010;11(1):121–5. PubMedCrossRef Gan-Or Z, Bar-Shira A, Mirelman A, Gurevich T, Kedmi M, Giladi N, et al. LRRK2 and GBA mutations differentially affect the initial presentation of Parkinson disease. Neurogenetics. 2010;11(1):121–5. PubMedCrossRef
59.
Zurück zum Zitat Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson disease center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99–105. PubMedCrossRef Szewczyk-Krolikowski K, Tomlinson P, Nithi K, Wade-Martins R, Talbot K, Ben-Shlomo Y, et al. The influence of age and gender on motor and non-motor features of early Parkinson’s disease: initial findings from the Oxford Parkinson disease center (OPDC) discovery cohort. Parkinsonism Relat Disord. 2014;20(1):99–105. PubMedCrossRef
60.
Zurück zum Zitat Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord. 2018;50:29–36. PubMedPubMedCentralCrossRef Cholerton B, Johnson CO, Fish B, Quinn JF, Chung KA, Peterson-Hiller AL, et al. Sex differences in progression to mild cognitive impairment and dementia in Parkinson’s disease. Parkinsonism Relat Disord. 2018;50:29–36. PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Zielonka D, Stawinska-Witoszynska B. Gender differences in non-sex linked disorders: insights from Huntington’s disease. Front Neurol. 2020;11:571. PubMedPubMedCentralCrossRef Zielonka D, Stawinska-Witoszynska B. Gender differences in non-sex linked disorders: insights from Huntington’s disease. Front Neurol. 2020;11:571. PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Beinhoff U, Tumani H, Brettschneider J, Bittner D, Riepe MW. Gender-specificities in Alzheimer’s disease and mild cognitive impairment. J Neurol. 2008;255(1):117–22. PubMedCrossRef Beinhoff U, Tumani H, Brettschneider J, Bittner D, Riepe MW. Gender-specificities in Alzheimer’s disease and mild cognitive impairment. J Neurol. 2008;255(1):117–22. PubMedCrossRef
63.
Zurück zum Zitat Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin‑1 mutant transgenes. Brain Res. 2004;1017(1–2):130–6. PubMedCrossRef Howlett DR, Richardson JC, Austin A, Parsons AA, Bate ST, Davies DC, et al. Cognitive correlates of Abeta deposition in male and female mice bearing amyloid precursor protein and presenilin‑1 mutant transgenes. Brain Res. 2004;1017(1–2):130–6. PubMedCrossRef
64.
Zurück zum Zitat Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685–91. PubMedCrossRef Barnes LL, Wilson RS, Bienias JL, Schneider JA, Evans DA, Bennett DA. Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry. 2005;62(6):685–91. PubMedCrossRef
65.
Zurück zum Zitat Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham study. Neurology. 1997;49(6):1498–504. PubMedCrossRef Seshadri S, Wolf PA, Beiser A, Au R, McNulty K, White R, et al. Lifetime risk of dementia and Alzheimer’s disease. The impact of mortality on risk estimates in the Framingham study. Neurology. 1997;49(6):1498–504. PubMedCrossRef
66.
Zurück zum Zitat Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM incidence research group. Neurology. 1999;53(9):1992–7. PubMedCrossRef Andersen K, Launer LJ, Dewey ME, Letenneur L, Ott A, Copeland JR, et al. Gender differences in the incidence of AD and vascular dementia: the EURODEM studies. EURODEM incidence research group. Neurology. 1999;53(9):1992–7. PubMedCrossRef
67.
Zurück zum Zitat Chene G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, et al. Gender and incidence of dementia in the Framingham heart study from mid-adult life. Alzheimers Dement. 2015;11(3):310–20. PubMedCrossRef Chene G, Beiser A, Au R, Preis SR, Wolf PA, Dufouil C, et al. Gender and incidence of dementia in the Framingham heart study from mid-adult life. Alzheimers Dement. 2015;11(3):310–20. PubMedCrossRef
68.
Zurück zum Zitat Hanamsagar R, Bilbo SD. Sex differences in neurodevelopmental and neurodegenerative disorders: focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol. 2016;160:127–33. PubMedCrossRef Hanamsagar R, Bilbo SD. Sex differences in neurodevelopmental and neurodegenerative disorders: focus on microglial function and neuroinflammation during development. J Steroid Biochem Mol Biol. 2016;160:127–33. PubMedCrossRef
69.
Zurück zum Zitat Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, et al. Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):363–71. PubMedPubMedCentralCrossRef Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, et al. Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis. 2013;35(2):363–71. PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Mastrokolias A, Ariyurek Y, Goeman JJ, van Duijn E, Roos RA, van der Mast RC, et al. Huntington’s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. Eur J Hum Genet. 2015;23(10):1349–56. PubMedPubMedCentralCrossRef Mastrokolias A, Ariyurek Y, Goeman JJ, van Duijn E, Roos RA, van der Mast RC, et al. Huntington’s disease biomarker progression profile identified by transcriptome sequencing in peripheral blood. Eur J Hum Genet. 2015;23(10):1349–56. PubMedPubMedCentralCrossRef
71.
Zurück zum Zitat Corey-Bloom J, Haque A, Aboufadel S, Snell C, Fischer RS, Granger SW, et al. Uric acid as a potential peripheral biomarker for disease features in Huntington’s patients. Front Neurosci. 2020;14:73. PubMedPubMedCentralCrossRef Corey-Bloom J, Haque A, Aboufadel S, Snell C, Fischer RS, Granger SW, et al. Uric acid as a potential peripheral biomarker for disease features in Huntington’s patients. Front Neurosci. 2020;14:73. PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Gutierrez A, Corey-Bloom J, Thomas EA, Desplats P. Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington’s disease patients. Front Mol Neurosci. 2020;12:335. PubMedPubMedCentralCrossRef Gutierrez A, Corey-Bloom J, Thomas EA, Desplats P. Evaluation of biochemical and epigenetic measures of peripheral brain-derived neurotrophic factor (BDNF) as a biomarker in Huntington’s disease patients. Front Mol Neurosci. 2020;12:335. PubMedPubMedCentralCrossRef
73.
Zurück zum Zitat Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26(1):115–23. PubMedCrossRef Lommatzsch M, Zingler D, Schuhbaeck K, Schloetcke K, Zingler C, Schuff-Werner P, et al. The impact of age, weight and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26(1):115–23. PubMedCrossRef
74.
Zurück zum Zitat Chang KH, Wu YR, Chen YC, Chen CM. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun. 2015;44:121–7. PubMedCrossRef Chang KH, Wu YR, Chen YC, Chen CM. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun. 2015;44:121–7. PubMedCrossRef
75.
Zurück zum Zitat Pekmezovic T, Svetel M, Maric J, Dujmovic-Basuroski I, Dragasevic N, Keckarevic M, et al. Survival of Huntington’s disease patients in Serbia: longer survival in female patients. Eur J Epidemiol. 2007;22(8):523–6. PubMedCrossRef Pekmezovic T, Svetel M, Maric J, Dujmovic-Basuroski I, Dragasevic N, Keckarevic M, et al. Survival of Huntington’s disease patients in Serbia: longer survival in female patients. Eur J Epidemiol. 2007;22(8):523–6. PubMedCrossRef
76.
Zurück zum Zitat Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P. Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol. 2012;259(9):1824–31. PubMedCrossRef Byars JA, Beglinger LJ, Moser DJ, Gonzalez-Alegre P, Nopoulos P. Substance abuse may be a risk factor for earlier onset of Huntington disease. J Neurol. 2012;259(9):1824–31. PubMedCrossRef
77.
Zurück zum Zitat Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991;48(8):800–4. PubMedCrossRef Myers RH, Sax DS, Koroshetz WJ, Mastromauro C, Cupples LA, Kiely DK, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991;48(8):800–4. PubMedCrossRef
78.
Zurück zum Zitat Cao JK, Detloff PJ, Gardner RG, Stella N. Sex-dependent behavioral impairments in the HdhQ350/+ mouse line. Behav Brain Res. 2018;337:34–45. PubMedCrossRef Cao JK, Detloff PJ, Gardner RG, Stella N. Sex-dependent behavioral impairments in the HdhQ350/+ mouse line. Behav Brain Res. 2018;337:34–45. PubMedCrossRef
79.
Zurück zum Zitat Pietropaolo S, Delage P, Cayzac S, Crusio WE, Cho YH. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice. PLoS One. 2011;6(5):e19965. PubMedPubMedCentralCrossRef Pietropaolo S, Delage P, Cayzac S, Crusio WE, Cho YH. Sex-dependent changes in social behaviors in motor pre-symptomatic R6/1 mice. PLoS One. 2011;6(5):e19965. PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Kuljis DA, Gad L, Loh DH, MacDowell Kaswan Z, Hitchcock ON, Ghiani CA, et al. Sex differences in circadian dysfunction in the BACHD mouse model of Huntington’s disease. PLoS One. 2016;11(2):e147583. PubMedPubMedCentralCrossRef Kuljis DA, Gad L, Loh DH, MacDowell Kaswan Z, Hitchcock ON, Ghiani CA, et al. Sex differences in circadian dysfunction in the BACHD mouse model of Huntington’s disease. PLoS One. 2016;11(2):e147583. PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, et al. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. PLoS One. 2014;9(8):e105595. PubMedPubMedCentralCrossRef Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, et al. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. PLoS One. 2014;9(8):e105595. PubMedPubMedCentralCrossRef
82.
Zurück zum Zitat Pfalzer AC, Wages PA, Porter NA, Bowman AB. Striatal cholesterol precursors are altered with age in female Huntington’s disease model mice. J Huntingtons Dis. 2019;8(2):161–9. PubMedPubMedCentralCrossRef Pfalzer AC, Wages PA, Porter NA, Bowman AB. Striatal cholesterol precursors are altered with age in female Huntington’s disease model mice. J Huntingtons Dis. 2019;8(2):161–9. PubMedPubMedCentralCrossRef
83.
Zurück zum Zitat Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington’s disease mice. Neurobiol Dis. 2014;69:248–62. PubMedCrossRef Mo C, Pang TY, Ransome MI, Hill RA, Renoir T, Hannan AJ. High stress hormone levels accelerate the onset of memory deficits in male Huntington’s disease mice. Neurobiol Dis. 2014;69:248–62. PubMedCrossRef
84.
Zurück zum Zitat Mo C, Renoir T, Pang TY, Hannan AJ. Short-term memory acquisition in female Huntington’s disease mice is vulnerable to acute stress. Behav Brain Res. 2013;253:318–22. PubMedCrossRef Mo C, Renoir T, Pang TY, Hannan AJ. Short-term memory acquisition in female Huntington’s disease mice is vulnerable to acute stress. Behav Brain Res. 2013;253:318–22. PubMedCrossRef
85.
Zurück zum Zitat Polyzos AA, Wood NI, Williams P, Wipf P, Morton AJ, McMurray CT. XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington’s disease is age- and sex- dependent. PLoS ONE. 2018;13(4):e194580. PubMedPubMedCentralCrossRef Polyzos AA, Wood NI, Williams P, Wipf P, Morton AJ, McMurray CT. XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington’s disease is age- and sex- dependent. PLoS ONE. 2018;13(4):e194580. PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Skillings EA, Morton AJ. Delayed onset and reduced cognitive deficits through pre-conditioning with 3‑nitropropionic acid is dependent on sex and CAG repeat length in the R6/2 mouse model of Huntington’s disease. J Huntingtons Dis. 2016;5(1):19–32. PubMedCrossRef Skillings EA, Morton AJ. Delayed onset and reduced cognitive deficits through pre-conditioning with 3‑nitropropionic acid is dependent on sex and CAG repeat length in the R6/2 mouse model of Huntington’s disease. J Huntingtons Dis. 2016;5(1):19–32. PubMedCrossRef
88.
Zurück zum Zitat Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease. Gene Ther. 2016;23(3):283–95. PubMedCrossRef Connor B, Sun Y, von Hieber D, Tang SK, Jones KS, Maucksch C. AAV1/2-mediated BDNF gene therapy in a transgenic rat model of Huntington’s disease. Gene Ther. 2016;23(3):283–95. PubMedCrossRef
Metadaten
Titel
Association between sex and Huntington’s disease: an updated review on symptomatology and prognosis of neurodegenerative disorders
verfasst von
Nimra Hasnain
MBBS Taha Bin Arif
Roha Shafaut
Faiza Zakaria
Syeda Zainab Fatima
Ibtehaj Ul Haque
Publikationsdatum
20.06.2022
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-022-00941-2